- Home
- KLRS vs GNTA Comparison
KLRS vs GNTA Comparison
Compare KLRS & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | GNTA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 41.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KLRS | GNTA |
|---|---|---|
| Price | $8.50 | $1.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.50 | N/A |
| AVG Volume (30 Days) | ★ 166.4K | 106.2K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $1.35 |
| 52 Week High | $12.90 | $10.00 |
Technical Indicators
Market Signals| Indicator | KLRS | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 71.30 | 31.23 |
| Support Level | $5.58 | $1.80 |
| Resistance Level | $6.27 | $1.77 |
| Average True Range (ATR) | 0.74 | 0.19 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 87.65 | 9.40 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.